Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S.

Int J Gen Med. 2014 Jan 29;7:89-101. doi: 10.2147/IJGM.S51800. eCollection 2014.

PMID:
24501543
[PubMed]
Free PMC Article
2.

Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.

Verstovsek S.

Postgrad Med. 2013 Jan;125(1):128-35. doi: 10.3810/pgm.2013.01.2628. Review.

PMID:
23391678
[PubMed - indexed for MEDLINE]
3.

Ruxolitinib: a new treatment option for myelofibrosis.

Ganetsky A.

Pharmacotherapy. 2013 Jan;33(1):84-92. doi: 10.1002/phar.1165. Review.

PMID:
23307549
[PubMed - indexed for MEDLINE]
4.

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.

Vaddi K, Sarlis NJ, Gupta V.

Expert Opin Pharmacother. 2012 Nov;13(16):2397-407. doi: 10.1517/14656566.2012.732998. Epub 2012 Oct 10. Review.

PMID:
23051187
[PubMed - indexed for MEDLINE]
5.

Practical management of patients with myelofibrosis receiving ruxolitinib.

Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, Verstovsek S.

Expert Rev Hematol. 2013 Oct;6(5):511-23. doi: 10.1586/17474086.2013.827413. Epub 2013 Oct 2. Review.

PMID:
24083419
[PubMed - indexed for MEDLINE]
6.

Emerging drugs for myelofibrosis.

Atallah E, Verstovsek S.

Expert Opin Emerg Drugs. 2012 Dec;17(4):555-70. doi: 10.1517/14728214.2012.748748. Review.

PMID:
23186315
[PubMed - indexed for MEDLINE]
7.

Ruxolitinib for myelofibrosis--an update of its clinical effects.

Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):638-45. doi: 10.1016/j.clml.2013.09.006. Epub 2013 Oct 2. Review.

PMID:
24238036
[PubMed - indexed for MEDLINE]
Free Article
8.

Clarifying the use of ruxolitinib in patients with myelofibrosis.

Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO.

Oncology (Williston Park). 2013 Jul;27(7):706-14. Review. Erratum in: Oncology (Williston Park). 2013 Aug;27(8):737.

PMID:
23977767
[PubMed - indexed for MEDLINE]
Free Article
9.

Treatment and management of myelofibrosis in the era of JAK inhibitors.

Keohane C, Radia DH, Harrison CN.

Biologics. 2013;7:189-98. doi: 10.2147/BTT.S34942. Epub 2013 Aug 20. Erratum in: Biologics. 2013;7:231.

PMID:
23990704
[PubMed]
Free PMC Article
10.

How I treat myelofibrosis.

Cervantes F.

Blood. 2014 Sep 16. pii: blood-2014-07-575373. [Epub ahead of print]

PMID:
25232060
[PubMed - as supplied by publisher]
11.

Optimizing the management of patients with myelofibrosis.

Manea PJ.

Clin J Oncol Nurs. 2014 Jun;18(3):330-7. doi: 10.1188/14.CJON.330-337.

PMID:
24867113
[PubMed - in process]
12.

Ruxolitinib for the treatment of myelofibrosis: its clinical potential.

Ostojic A, Vrhovac R, Verstovsek S.

Ther Clin Risk Manag. 2012;8:95-103. doi: 10.2147/TCRM.S23277. Epub 2012 Mar 1.

PMID:
22399854
[PubMed]
Free PMC Article
13.

Clinical and laboratory features of myelofibrosis and limitations of current therapies.

Gregory SA, Mesa RA, Hoffman R, Shammo JM.

Clin Adv Hematol Oncol. 2011 Sep;9(9 Suppl 22):1-16.

PMID:
22362131
[PubMed - indexed for MEDLINE]
14.

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.

Tibes R, Mesa RA.

J Hematol Oncol. 2014 Mar 5;7:18. doi: 10.1186/1756-8722-7-18.

PMID:
24598114
[PubMed - in process]
Free PMC Article
15.

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

Jaekel N, Behre G, Behning A, Wickenhauser C, Lange T, Niederwieser D, Al-Ali HK.

Bone Marrow Transplant. 2014 Feb;49(2):179-84. doi: 10.1038/bmt.2013.173. Epub 2013 Dec 2.

PMID:
24292520
[PubMed - in process]
16.

Emerging therapeutic options for myelofibrosis: a Canadian perspective.

Gupta V, Foltz L, Sirhan S, Busque L, Turner AR.

Am J Blood Res. 2012;2(3):170-86. Epub 2012 Sep 23.

PMID:
23119228
[PubMed]
Free PMC Article
17.

Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.

Mascarenhas J, Mughal TI, Verstovsek S.

Curr Med Chem. 2012;19(26):4399-413. Review.

PMID:
22830345
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Novel myelofibrosis treatment strategies: potential partners for combination therapies.

Stein BL, Swords R, Hochhaus A, Giles F.

Leukemia. 2014 Jun 3. doi: 10.1038/leu.2014.176. [Epub ahead of print]

PMID:
24888274
[PubMed - as supplied by publisher]
19.

Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.

Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S.

J Hematol Oncol. 2012 Aug 1;5:43. doi: 10.1186/1756-8722-5-43. Review.

PMID:
22852872
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.

Tefferi A.

Am J Hematol. 2013 Feb;88(2):141-50. doi: 10.1002/ajh.23384. Review. Erratum in: Am J Hematol. 2013 May;88(5):437-45.

PMID:
23349007
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk